Artificial intelligence (AI) is profoundly transforming the paradigm of solid tumor drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, AI has significantly accelerated the discovery and validation of new targets, compressing the traditional ten-year research and development cycle to two to three years. Generative AI platforms have optimized small molecule inhibitors, biologics, and messenger RNA vaccines, achieving breakthroughs in overcoming tumor heterogeneity, improving efficacy, and predicting drug resistance. However, clinical translation still faces challenges such as data bias, algorithm transparency, and the validation gap between models and real-world human experience. This review aims to systematically elaborate on the transformative role of AI in solid tumor drug development and to promote interdisciplinary cooperation as well as the construction of ethical frameworks to enable the full realization of precision oncology.

Conversational AIs are getting better at sounding human. But when their goals misalign with ours, the consequences can be surprisingly personal.

Nvidia is on track to become the first $5 trillion company, just three months after the Silicon Valley chipmaker was first to break through the $4 trillion barrier.

Health systems and insurance companies are using artificial intelligence to analyze CT scans and MRIs, update electronic health records and review coverage decisions.

Amazon laying off 14,000 workers and citing efficiency gains from AI is just the beginning.

The eight BATMMAAN names are now worth nearly 40% of the S&P 500, as key AI players take flight once more….

As Amazon slashes 14,000 white-collar roles and the U.S. approaches a million job cuts this year, AI’s first major labor casualty might be emerging.

US chip giant’s stock propelled by strong sales of AI systems and prospect of access to China

Complex restructuring pays Microsoft handsomely but it’s unclear how other shareholders will fit into the AI love-in

A major announcement from the country’s second biggest private employer says it will slash its corporate workforce by 14,000 people. One of the reasons for the cuts? Artificial intelligence. And more companies may follow.